64517-88-0

Usage

Uses

Used in Pharmaceutical Industry:
1,3-DIMETHYL-1H-PYRAZOL-4-AMINE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
1,3-DIMETHYL-1H-PYRAZOL-4-AMINE is used as a building block in the production of agrochemicals, enabling the creation of effective compounds for agricultural applications such as pesticides.
Used in Chemical Industry:
1,3-DIMETHYL-1H-PYRAZOL-4-AMINE is used as a stabilizer and antioxidant in the production of polymers and plastics, enhancing the durability and performance of these materials.
Used in Organic Synthesis:
1,3-DIMETHYL-1H-PYRAZOL-4-AMINE is used as a reagent in organic synthesis, facilitating the creation of a wide range of organic compounds for various applications across different industries.

Upstream product

• 3920-38-5 1,3-dimethyl-4-nitro-1H-pyrazole 
• 694-48-4 1,3-dimethyl-1H-pyrazole 
• 74-88-4 methyl iodide 
• 5334-39-4 3-methyl-4-nitro-1H-pyrazole 

Downstream Products

• 1201934-67-9 2-[[2-[(2,5-dimethylpyrazol-3-yl)amino]-5-(trifluoromethyl)-4-pyridyl]amino]-N-methyl-benzamide 
• 1201933-67-6 2-((5-cyano-2-((1,3-dimethylpyrazol-4-yl)amino)-4-pyridyl)amino)-N-methyl-benzamide 
• 1201933-69-8 2-((5-cyano-2-((1,3-dimethylpyrazol-4-yl)amino)-4-pyridyl)amino)-N-methoxy-N-methyl-benzamide 
• 1201933-78-9 2-({5-Chloro-2-[(1,3-dimethyl-1H-pyrazol-4-yl)-amino]-4-pyridinyl}amino)-N-(methyloxy)benzamide 
• 1201934-20-4 2-((5-chloro-2-((1,3-dimethylpyrazol-4-yl)amino)-4-pyridyl)amino)-3-fluoro-N-methyl-benzamide 
• 1201934-21-5 2-((5-chloro-2-((1,3-dimethylpyrazol-4-yl)amino)-4-pyridyl)amino)-6-fluoro-N-methyl-benzamide 
• 1453848-11-7 (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1,3-dimethyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 1618664-02-0 4-(4-cyclobutoxy-2-((1,3-dimethyl-1H-pyrazol-4-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-N-methylbenzamide 
• 1566543-01-8 1-(2-(2-(5-chloro-2-((1,3-dimethyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)ethyl)phenyl)cyclopropanecarboxamide 
• 1453853-28-5 (S)-1-(2-(tert-butyldimethylsilyloxy)-1-(4-chloro-3-fluorophenyl)ethyl)-4-(2-(( 1,3-dimethyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one 
• 948571-12-8 N-(1,3-dimethyl-1H-pyrazol-4-yl)-2-[2-methoxy-4-(7-methoxyquinolin-4-yloxy)phenyl]acetamide 

Relevant academic research and scientific papers

Alkynyl pyrimidine or alkynyl pyridine compound as well as composition and application thereof

The invention relates to alkynyl pyrimidine or alkynyl pyridine compounds represented by a formula (I) or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof. The invention also discloses a pharmaceutical composition contain

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives

The c-jun N-terminal kinase 3 (JNK3) is expressed primarily in the brain. Numerous reports have shown that inhibition of JNK3 is a promising strategy for treatment of neurodegeneration. The optimization of aminopyrazole-based JNK3 inhibitors with improved potency, isoform selectivity, and pharmacological properties by structure-activity relationship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is reported. These inhibitors had high selectivity over JNK1 and p38α, minimal cytotoxicity, potent inhibition of 6-OHDA-induced mitochondrial membrane potential dissipation and ROS generation, and good drug metabolism and pharmacokinetic (DMPK) properties for iv dosing. 26n was profiled against 464 kinases and was found to be highly selective hitting only seven kinases with >80% inhibition at 10 μM. Moreover, 26n showed good solubility, good brain penetration, and good DMPK properties. Finally, the crystal structure of 26k in complex with JNK3 was solved at 1.8 ? to explore the binding mode of aminopyrazole based JNK3 inhibitors.

HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS

The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.